The Company’s growth capital of $290 million was provided through credits negotiated by Koeninger with senior lenders, including a $150 million Term B loan.
Through his CFO position at RTSI, combined with his prior 12-year career with Anthem Blue Cross and Blue Shield and its predecessor, Community Mutual Insurance Company of Ohio, Mr. Koeninger has experience in developing the financial infrastructure required to support a high-growth privately owned company, as well as one with a public profile. Koeninger also led the initial response to the requirements of the Sarbanes-Oxley Act at RTSI, including Section 404 reporting on internal control over financial reporting.
David Koeninger is a certified public accountant licensed in the states of Florida and Kentucky and began his career in Cincinnati, Ohio as an auditor at Ernst & Young, CPAs. He holds a Master of Accountancy degree from Virginia Tech and completed his bachelor’s degree in business administration at Eastern Kentucky University.
Full biographies, unique experience, expertise & accomplishments of each advisory board member:
- Neil J. Campbell,
M.A., M.B.A. – Chairman - Kevin Carroll
- Edward L. Erickson
- Daniel D'Agostino
- Nigel Gaymond, M.A.
- David M. Koeninger
- Udo Klein, Ph.D.
- Stefan Loren, Ph.D.
- Kevin Nickels
- Rick Pierce
- Robin Pratt, Ph.D.
- Linda M. Pullan, Ph.D.
- Dane Saglio, C.P.A.
- Peter G. Savas
- Chris Ward
- Ruth Williams, Esq.
David M. Koeninger is a healthcare consultant specializing in the business of radiation oncology.
Prior to his consulting practice, Mr. Koeninger served as executive vice president and CFO of Radiation Therapy Services, Inc. (RTSI), a Ft. Myers-based developer and operator of radiation therapy clinics providing advanced medical treatment services to cancer patients. RTSI introduced the public markets to their specialized area of oncology services as a NASDAQ-traded company in 2004. Mr. Koeninger led the development of the Company’s investor-relations program at RTSI by presenting at more than 25 conferences and hosting more than 300-plus individual account meetings and visits, as well as expanding the number of equity research analysts covering the Company from four at the time of the 2004 IPO to ten in June 2007.
As a high-growth company, RTSI expanded its annual revenues from less than $50 million to more than $300 million during Koeninger’s nine years as CFO and completed the acquisition of more than 40 treatment centers; he also oversaw the Company’s expansion from 18 treatment centers to over 80.
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||